SCHEMBL6926720

SCHEMBL6926720

OC1CCN(CCOc2cccc3c2c2ccccc2n3Cc2ccccc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HTR1A P08908 1/20 0.45
HTR1D P28221 1/20 0.45
HTR1B P28222 1/20 0.45
DRD2 P14416 1/20 0.45
HTR6 P50406 1/20 0.45
SIGMAR1 Q99720 6/20 0.45
DRD4 P21917 1/20 0.44
LTA4H P09960 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.44
ESR1 P03372 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6920002 0.88 HRH1 (0.53) HTR1AHTR1DHTR1BDRD2DRD4
SCHEMBL6920834 0.87 LMNA (0.52) KDM4EMEN1ALDH1A1KMT2AHTR1A
SCHEMBL6926928 0.87 ESR1 (0.54) HTR1AHTR1DHTR1BDRD2HTR6
SCHEMBL7505923 0.86 ACHE (0.51) MEN1KMT2AHTR1AHTR1DHTR1B
SCHEMBL6926761 0.86 HTR1A (0.53) KDM4EMEN1ALDH1A1KMT2AHTR1A
SCHEMBL6927454 0.85 LTA4H (0.49) KDM4EMEN1ALDH1A1KMT2AHTR1A
SCHEMBL6925328 0.85 DRD1 (0.56) KDM4EHTR1AHTR1DHTR1BDRD4
SCHEMBL6924579 0.84 ALDH1A1 (0.50) KDM4EMEN1ALDH1A1KMT2AHTR1A
SCHEMBL6923678 0.82 PLA2G2A (0.50) KDM4EMEN1ALDH1A1KMT2AHTR1A
SCHEMBL6923676 0.80 HTR1A (0.45) KDM4EMEN1ALDH1A1KMT2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US claimed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP claimed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO claimed
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US disclosed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP disclosed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO disclosed